GLP-1 drugs were also linked with better graft and patient survival in kidney transplant recipients with type 2 diabetes.

Beyond type 2 diabetes and weight loss, GLP-1 agonists can also help lower blood pressure, improve lipid disorders, reduce ...

A large population-based cohort study reports that using GLP-1 RAs significantly reduces the risk for cardiovascular events ...

Patients with T2D who undergo kidney transplants are less likely to experience organ failure and mortality if they receive ...

With respect to risks, GLP-1RA use was significantly associated with an increased risk of gastrointestinal disorders, hypotension, syncope, arthritic disorders, drug-induced pancreatitis, and other ...

Coverage of GLP-1s is not necessarily in-your-face obvious. It leads to the conversation of whether we want to pursue weight ...

Researchers found that GLP-1 receptor agonists (GLP-1RAs) significantly reduce the risk of several blood cancers in type 2 ...

Kidney transplant recipients with type 2 diabetes treated with a new class of anti-obesity drugs were less likely to experience organ failure and survived longer, a new study shows.

A groundbreaking study shows that GLP-1 agonist anti-obesity drugs not only aid weight loss but significantly improve ...

GLP-1 drugs like Ozempic can help kidney transplant patients avoid organ failure and live longer, a new study sugges ...

While drug developers work to mitigate the side effects associated with GLP-1–based obesity drugs, recent studies reveal that ...